- $390.46m
- $258.57m
- $0.02m
Annual cashflow statement for Altimmune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -49 | -97.1 | -84.7 | -88.4 | -95.1 |
| Depreciation | |||||
| Non-Cash Items | 18.8 | 18.6 | 8.02 | 20.4 | 10.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.51 | -0.251 | 14.1 | -8.27 | 4.48 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -34.3 | -78.2 | -62.6 | -75.8 | -79.8 |
| Capital Expenditures | -0.342 | -12.3 | -0.126 | -0.047 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -71.9 | 99.8 | -73.3 | 13.8 | -28.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -72.2 | 87.5 | -73.4 | 13.7 | -28.4 |
| Financing Cash Flow Items | 0 | -0.119 | 0 | -0.824 | -0.85 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 213 | 65.1 | 56.8 | 86.1 | 10 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 107 | 74.4 | -79.2 | 24 | -98.2 |